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EpilepsyThe role of interleukin 17 (IL-17) to epilepsy-associated cortical tubers of tuberous sclerosis complex (TSC) is
unknown. We investigated the expression patterns of the IL-17 and IL-17 receptor (IL-17R) in cortical tubers
of TSC compared with normal control cortex (CTX). We found that IL-17 and IL-17R were clearly upregulated
in cortical tubers at the protein levels. Immunostaining indicated that IL-17 was speciﬁcally distributed in the
innate immunity cells (DNs, GCs, astrocytes, and microglia) and adaptive immunity cells (T-lymphocytes) as
well as the endothelial cells of blood vessels. The overexpression and distribution patterns of IL-17 may be
involved in the epileptogenicity of cortical tubers in TSC.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant disor-
der resulting frommutations in one of two genes, TSC1 (which encodes
hamartin) and TSC2 (which encodes tuberin), and is characterized by
hamartoma formation in multiple organs, including the skin, eyes, kid-
ney, heart, and brain(Crino et al., 2006). Neurological involvement usu-
ally accounts for the most disabling symptoms of the disease, such as
intellectual disabilities, autism, and epilepsy. Epilepsy has a high preva-
lence in TSC, occurring inmore than 70% to 80% of patients (Crino et al.,
2006; Curatolo et al., 2008). Patients with TSC can havemultiple seizure
types (including generalized, focal, or multifocal seizures) and are re-
fractory to the currently available antiepileptic drugs (AEDs) (Crino et
al., 2006). Histopathological examination of TSC brain specimens re-
veals cortical tubers, subependymal nodules, and subependymal giant
cell astrocytomas (SEGAs). Cortical tubers, a typical pathological hall-
mark of TSC in the brain, are regions of focal cortical dysplasia present-
ing with disorganization or lacking of the normal six-layered cortical
lamination structure, astrogliosis, abnormal cells including dysplastic
neurons (DNs), with aberrant somatodendritic morphologies, and
giant cells (GCs, also named TS-cells) with short thickened processes
(Mizuguchi and Takashima, 2001). Moreover, cortical tubers are often
identiﬁed as source of seizures and require surgical therapy (Luat et
al., 2007). An understanding of the molecular events that underlie they, Xinqiao Hospital, Third Mili-
ba District, Chongqing 400037,
.V. Open access under CC BY license.occurrence of seizures is essential for devising new therapeutic ap-
proaches for the treatment of epilepsy.
The expression of proinﬂammatory cytokines is upregulated in cor-
tical tubers of TSC, and plays a critical role in generating seizures (Boer
et al., 2008, 2010). IL-17, also referred to as IL-17A, is a prototypicmem-
ber of the newest subclass of cytokines. IL-17 acts as a proinﬂammatory
cytokine that can induce the release of certain chemokines and cyto-
kines (e.g., IL-1β, IL-6, TNF-α) and has a distinct ligand–receptor system
(IL-17R) (Xu and Cao, 2010). Several studies have demonstrated that
IL-17 can play a bridging role between innate and adaptive immunity
in vivo and that IL-17 induces blood–brain barrier (BBB) disruption
and promotes neuronal injury through an IL-17/IL-17R combination in
multiple sclerosis and ischemic brain injury (Kolls and Linden, 2004;
Kebir et al., 2007; Wang et al., 2009; Xu and Cao, 2010). Activation of
both the innate and adaptive immune responses has been accepted as
a striking feature that occurs in epilepsy-associated cortical tuber and
that the inﬂammatory response may contribute to the generation and
recurrence of seizures (Boer et al., 2008; Rodgers et al., 2009). Recent
evidence suggests that BBB disruption is associated with inﬂammation
in TSC-associated lesions, which facilitates neuronal hyperexcitability
and epileptiform activity (Boer et al., 2008). There is activation of the
mammalian target of rapamycin (mTOR) signaling pathway in TSC. In-
terestingly, rapamycin, a potent speciﬁc inhibitor of themTOR signaling
system, strongly inhibits the induction of IL-17 in T lymphocytes
(Yurchenko et al., 2012) which was observed in cortical tubers (Boer
et al., 2008). In addition, our previous study revealed that there are in-
creased levels of IL-17 and IL-17R protein in cortical lesions of focal cor-
tical dysplasias (FCDs) (He et al., 2013), which are recognized to be
causes of pediatric intractable epilepsy. Moreover, FCDIIb and TSC do
share a number of characteristic cellular and histological abnormalities
as well as common clinical features. Accordingly, we hypothesize that
86 J.-J. He et al. / Journal of Neuroimmunology 262 (2013) 85–91IL-17may play a key role in the epileptogenesis andmay represent a po-
tential anti-epileptogenic target. Therefore, the identiﬁcation of IL-17
and IL-17R in the epileptic foci would provide a new basis for TSC
epileptogenicity.
In the present study, we analyzed the protein levels of IL-17 and
IL-17R in cortical tubers from patients with medically intractable
epilepsy. In addition, we investigated the speciﬁc cellular distribution
of IL-17 and IL-17R in this lesion.2. Materials and methods
2.1. Subjects
The cases in this study were obtained from the Department of
Neurosurgery of the Xinqiao Hospital (Third Military Medical Univer-
sity, Chongqing, China). All of the procedures and experiments were
conducted under the guidelines approved by the Ethics Committee
of the Third Military Medical University. All of the human brain tissue
was obtained and used in a manner compliant with the Declaration of
Helsinki. No tissue was resected solely for experimental purposes. A
total of 16 TSC surgical specimens were obtained from patients un-
dergoing surgery for intractable epilepsy. All of the cases were inde-
pendently reviewed by two neuropathologists, and the diagnoses of
TSC were in accordance with the diagnostic criteria for TSC (Crino et
al., 2006). Furthermore, clinical mutation analyses of the TSC1 and
TSC2 loci were performed by means of denaturing high performance
liquid chromatography (DHPLC) to conﬁrm our diagnoses. In this
study, all of the patients did not have seizure activity in the last
24 h before surgery. Seizure outcome was assessed using Engel's et
al. criteria. All patients underwent surgery and had a follow-up at
least 1 year later. The detailed clinical data for each specimen are
listed in Table 1.
For comparison, normal-appearing cortex (i.e., CTX) andwhitemat-
ter were obtained at autopsy from 10 patients (5 female, 5 male; mean
age: 5.5 years, range: 2.4–10.8 years) who did not have a history of
seizures or other neurological diseases. All of the autopsies were
performed within 6 h of death. Two neuropathologists also helped to
review the control cases, and both gross and microscopic examinations
revealed no abnormalities. The clinical data for the normal control tis-
sues are summarized in Supplemental Table 1.Table 1
Clinical and neuropathological characteristics of patients with TSC.
Case no. Sex Pathology Genotype Age at
surgery
(year)
Epilepsy
duration
(years)
Seizure type
1 F TSC TSC2 1.1 0.8 IS
2 M TSC TSC1 1.8 0.9 PS
3 M TSC TSC2 2.5 0.8 PS
4 F TSC TSC1 3.1 2.5 IS, GTCS
5 M TSC TSC2 4.2 2.5 PS, IS
6 F TSC TSC1 4.6 3.5 PS, GTCS
7 F TSC TSC2 4.6 3.5 PS, IS
8 M TSC TSC2 5.2 3.5 PS
9 M TSC TSC2 5.6 4.5 GTCS
10 M TSC TSC2 6.4 4.3 PS
11 F TSC TSC2 7.6 6.0 PS, GTCS
12 M TSC TSC2 8.2 6.9 PS
13 F TSC NMI 8.5 6.2 PS, Tonic
14 F TSC TSC1 9.7 3.0 PS
15 M TSC TSC2 11.3 4.9 Tonic
16 M TSC NMI 11.5 8 PS, GTCS, Tonic
TSC, tuberous sclerosis complex; AEDs, antiepileptic drugs; PO, postoperative outcome (Eng
generalized tonic–clonic seizure; PS, partial seizure; IS, infantile spasm; F, frontal lobe; P, pa
phenobarbital; TPM, topiramate; ACTH, adrenocorticotropic hormone; VPA, valproate; OxCZ
blotting; IHC, immunohistochemistry (including immunoﬂuorescence).2.2. Tissue preparation
All brain samples obtained at surgery or autopsy were immediately
divided into two parts. One part was immediately placed in a cryovial
that had been soaked in buffered diethylpyrocarbonate (1:1000) for
24 h and was then snap-frozen in liquid N2. The frozen samples were
maintained at −80 °C until they were used for Western blotting. The
remaining part of the sample was ﬁxed in 10% buffered formalin for
24 h andwas then embedded in parafﬁn. The parafﬁn-embedded tissue
was sectioned at 5 μm for histological and immunohistochemical stain-
ing, or 10 μm for double immunoﬂuorescence staining.2.3. Western blotting analysis
Western blotting analyses were performed to quantify the amount
of IL-17 and IL-17R protein in homogenates from TSC cortical tubers
(n = 16), and CTX samples (n = 10). β-actin levels were evaluated as
a loading control. The frozen samples were dissected on a freezing
table and homogenized. The tissue homogenates were lysed in RIPA
buffer containing 10 mM Tris (pH 8.0), 150 mM NaCl, 10% glycerol, 1%
NP-40, 0.4 mg/ml Na-orthovanadate, 5 mMethylenediaminetetraacetic
acid (EDTA) (pH 8.0), 5 mM NaF and 10% protease inhibitor cocktail
(Sigma, St. Louis, MO). The protein concentration was determined
using the bicinchoninic acid protein assay (Bio-Rad, Hercules, CA,
USA). For electrophoresis, equal amounts of protein (30 μg/lane) were
separated by sodiumdodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) analysis in 6%, 10% or 12% polyacrylamide gel depending
on the target protein. The separated proteins were transferred onto
polyvinylidene ﬂuoride membranes (Millipore, Temecula, CA, USA)
using a semi-dry electroblotting system (Transblot SD; Bio-Rad). For
immunoblotting, the membranes were blocked in 5% nonfat dry milk
for 1 h and incubated overnight at 4 °C with one of the following
primary antibodies: β-actin (rabbit monoclonal, 1:1000; Santa Cruz,
CA, USA), IL-17 (rabbit monoclonal, 1:1000;Millipore), or IL-17R (rabbit
polyclonal, 1:400; Santa Cruz). After several washes in Tris-buffered
saline containing 0.5% Tween-20 (TBST), the samples were treated
with horseradish peroxidase-conjugated goat anti-rabbit secondary an-
tibody (1:1000; Zhongshan Goldenbridge Biotechnology Co, Beijing,
China) for 1 h at room temperature. The antibody labeling was visual-
ized using enhanced chemiluminescence.Epileptogenic
lesion location
Seizure
frequency
(per month)
AEDs PO Application in
present study
F 75 VPA, CBZ, CLZ, ACTH II WB, IHC
P 25 VPA, CLZ I WB, IHC
P 10 VPA, TPM, LMT I WB, IHC
F 10 VPA, ACTH, PHT, LMT II WB, IHC
T 135 TPM, LEV, ACTH I WB, IHC
O 30 CBZ, VPA, ACTH I WB, IHC
T 120 VPA, TPM, LMT III WB, IHC
F, O 30 VPA, LEV I WB, IHC
T 15 VPA, CLZ I WB, IHC
F 60 VPA, TPM, LMT I WB, IHC
F 10 TPM, CBZ I WB, IHC
T 75 VPA, TPM, PB I WB, IHC
O 85 VPA, CLZ II WB, IHC
P, T 20 CBZ, VPA I WB, IHC
F 5 OxCZ, VPA IV WB, IHC
T 10 VPA, LEV, CLZ III WB, IHC
el's class); F, female; M, male; NMI: No Mutation Identiﬁed by genetic analysis; GTCS,
rietal lobe; O, occipital lobe; T, temporal lobe; PHT, phenytoin; CBZ, carbamazepine; PB,
, oxcarbazepine; LEV, levetiracetam; LMT, lamotrigine; CLZ, clonazepam; WB, Western
87J.-J. He et al. / Journal of Neuroimmunology 262 (2013) 85–91For the immunoblotting analyses, densitometry was performed
with Image-Pro Plus software (Media Cybernetics, Silver Spring,
MD). The optical densities (ODs) of the protein bands were calculated
relative to the ODs of the reference protein, β-actin.
2.4. Histology and immunohistochemistry
Parafﬁn sections were mounted on polylysine-coated slides.
Two slices in each parafﬁn block were routinely stained with hema-
toxylin and eosin (H&E), and consecutive serial sections were used
for immunohistochemistry (IHC). The parafﬁn-embedded sections
were deparafﬁnized, rehydrated, and incubated for 30 min in 0.3%
H2O2 diluted inmethanol to quench any endogenous peroxidase activity.
All of the samples were placed in phosphate buffered saline (PBS)
(0.01 M, pH 7.3) and heated in a microwave oven for antigen retrieval.
The sections were washed with PBS and incubated for 60 min in 10%
normal goat serum at room temperature, followed by incubation with
primary rabbit anti-human IL-17 (rabbit polyclonal, 1:100; Santa Cruz)
or IL-17R (rabbit polyclonal, 1:100; Santa Cruz) overnight at 4 °C. After
3 rinses with PBS, the sections were incubated with goat anti-rabbit
immunoglobulin conjugated to peroxidase-labeled dextran polymer
(EnVision + System-HRP; Boster, Wuhan, China) for 60 min at 37 °C.
The immunoreactions were visualized using 3,3-diaminobenzidine
(Boster). The sections were counterstained with hematoxylin,
dehydrated, and cover-slipped. No immunoreactive cells were detected
in the negative control experiments including secondary antibody
alone, pre-absorption with a 10-fold excess of speciﬁc blocking antigen
or incubation with an isotype-matched rabbit polyclonal antibody. A
LeicaDMIRBmicroscope (LEICA,Nussloch, Germany)was used to capture
the images of the sections.
For double immunoﬂuorescence staining, the parafﬁn-embedded
sections were incubated for 1 h at room temperature followed by over-
night incubation at 4 °C with primary anti-IL-17 combined with anti-
GFAP (mousemonoclonal, 1:500; Sigma), anti-NF200 (mousemonoclo-
nal, 1:100; Boster), anti-HLA-DP, DQ, DR (mouse monoclonal, 1:100,
Dako, Glostrup, Denmark), anti-CD4 (mouse monoclonal, 1:50; Dako)
or anti-CD8 (mousemonoclonal, 1:40; Dako) and anti-IL-17R combined
with anti-GFAP or anti-NF200. After 3 washes with PBS, the sections
were incubated with a mixture of FITC-conjugated goat anti-rabbit IgG
(1:300; Zhongshan Goldenbridge Biotechnology Co) and Alexa Fluor
594 goat anti-mouse IgG (1:500, Invitrogen) for 1 h at 37 °C. Next, the
sections were mounted with Vectashield containing DAPI (10 μg/ml,
Beyotime, China) to label DNA in cell nuclei. The ﬂuorescent sections
were observed and photographedwith a confocal laser scanningmicro-
scope (TCS-TIV; Leica, Nussloch, Germany).
2.5. Evaluation of immunostaining and cell counting
All of the labeled tissue sections were evaluated as previously
reported (Zurolo et al., 2011) using a Leica DMIRB microscope to
examine a total microscopic area of 781.250 μm2 (200 high-power
non-overlapping ﬁelds of 0.0625 × 0.0625 mm width, using a square
grid inserted into the eyepiece). The intensity of the IL-17 and IL-17R
immunoreactivity (IR) was evaluated using a semi-quantitative three-
point scale in which IR was deﬁned as follows: ― absent (0), + weak
(1), ++ moderate(2), or +++ strong (3) (Table 2). These scores
represent the predominant staining intensity in each section and wereTable 2
Staining scores of IL-17 and IL-17R immunopositive cells in TSC specimens.
CTX (n = 10) TSC (n = 16)
IL-17 0.83 ± 0.24 2.27 ± 0.42⁎⁎
IL-17R 0.62 ± 0.17 2.36 ± 0.25⁎⁎
Data are expressed as mean ± SEM.
⁎⁎ P b 0.001, TSC versus CTX, ANOVA.calculated as the averages of the selected ﬁelds. Additionally, we calcu-
lated the labeling index (LI) of IL-17 and IL-17R positive cells in the TSC
cortical tubers as previously described (Schick et al., 2007). The LI was
deﬁned as the ratio of the immunolabeled cells to the entire target
cell population.2.6. Data analysis and statistics
All of the data are expressed as the means ± SEM. The statistical
analyses were performed with the Statistical Products and Service
Solution package (SPSS for Windows, version 13.0, SPSS Inc., Chicago,
IL, USA). The differences between the experimental groups were ana-
lyzed by one-way analysis of variance (ANOVA). P b 0.05 was consid-
ered to be signiﬁcant.3. Results
3.1. Case material and histological features
The clinical features of the tissues obtained from the TSC that were
used in this study are summarized in Table 1. All of the patients
underwent surgery for intractable epilepsy, and most were complete-
ly seizure-free following surgery. The cortical tubers of TSC cases in
this study were histologically composed of abnormal cortical laminar
architecture, astrogliosis, DNs, and GCs (see Supplemental Fig. 1B).
The DNs were identiﬁed as neurons with abnormal morphology, en-
larged somal size, abnormal orientation, abnormal dendritic patterns,
and abundant Nissl substances. The GCs, a unique cell type, were de-
ﬁned as morphologically abnormal cells with a thin membrane, eo-
sinophilic cytoplasm, no clear axonal or dendritic processes, and one
or more eccentrically located nuclei. At low magniﬁcation, the CTX
with H&E staining has organized layers with well-preserved lamina-
tions and a unipolar orientation of apical dendrites toward the pial
surface as well as normal deﬁnition of the gray-white matter junction
(see Supplemental Fig. 1A).3.2. Western blotting analysis of IL-17 and IL-17R
We examined the expression of the IL-17 system at the protein
level by Western blot analysis in cortical tubers of TSC. Fig. 1A
shows that IL-17 and IL-17R were present as bands of approximately
32 kDa and 120 kDa, respectively. There was a notable increase in
IL-17 and IL-17R expression in the cortical tubers compared with
CTX samples (Fig. 1B).Fig. 1. Changes in IL-17 and IL-17R expression in cortical tubers of TSC. (A) Represen-
tative immunoblot bands and (B) densitometric analyses of total homogenates from
TSC tubers and CTX tissues. *P b 0.05 and **P b 0.01 versus CTX, ANOVA.
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Weak to moderate IL-17 IR was detected in neurons and glial cells
throughout all of the cortical layers in the CTX specimens (Fig. 2A, B);
weak staining was observed in the endothelial cells of blood vessels
(Fig. 2A, inset).
In the cortical tuber, there was strong IL-17 IR in 89% ± 2.1% of
the DNs (n = 584) (Fig. 2C, D) and in 91% ± 1.3% of the GCs (n =
409) (Fig. 2C, D), along with moderate to strong IL-17 IR in the glial
cells (Fig. 2C, D). Additionally, strong IL-17 IR staining was found in
the endothelial cells of blood vessels (Fig. 2C, inset). The intensity
scores of IL-17 IR in the cortical tuber were dramatically higher thanFig. 2. Cell-speciﬁc distribution of IL-17 in cortical tubers of TSC. (A and B) IL-17 IR in CTX. W
weak IL-17 IR in endothelial cells (inset, A) in gray matter (GM) and white matter (WM).
(arrows in C, D and inset b in D) and GCs (double arrows in C, D and inset a in D). Modera
the colocalization of IL-17 (green) with GFAP (red) in glial cells (arrowheads in E) and H
image showing IL-17 IR DNs (F) and GCs with different sizes and shapes (G and H) colab
IL-17 (green) with CD4 (red, arrows in J) but not CD8 (red, arrows in K) in T-lymphocytes.
(A–D) 50 μm; (E, K) 30 μm; and (F–J) 20 μm.those in the CTX samples (Table 2). Double-labeling experiments
revealed that NF200-positive (NF200+) DNs (Fig. 2F) and GCs (Fig. 2G,
H) both expressed IL-17. Moreover, most of the IL-17+ glial cells were
the GFAP+ astrocytes (Fig. 2E) and HLA+ microglia (Fig. 2I). In this
study, we also observed a few CD4+ (Fig. 2J) but not CD8+ (Fig. 2K)
cells that expressed IL-17 in the TSC specimens.3.4. IL-17R immunoreactivity in cortical tubers of TSC
In the control specimens, weak to moderate IL-17R IR expression
was detected in neurons throughout all of the cortical layers (Fig. 3A).eak to moderate IL-17 IR in neurons (arrows in A) and glial cells (arrowheads in B), and
(C and D) IL-17 IR in TSC. Strong IL-17 IR in glial cells (arrowheads in C and D), DNs
te to strong IL-17 IR in endothelial cells (inset, C). (E and I) The merged images show
LA (red) in microglia (arrowheads in I) but not in DNs (arrows in I). (F–H) Confocal
eled with NF200 (red). (J and K) Double labeling staining shows the colocalization of
Sections are counterstained with hematoxylin (A–D) or DAPI (E–K). The bars indicate
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and in the endothelial cells of blood vessels (Fig. 3B, inset).
In the cortical tuber, there was a moderate to strong IL-17R IR in
85% ± 2.3% of the GCs (n = 427) (Fig. 3C), and strong expression
was detected in 87% ± 1.5% of the DNs (n = 606) (Fig. 3D) and in
the glial cells (Fig. 3C). In addition, moderate to strong staining was
observed in the endothelial cells of blood vessels (Fig. 3C, inset).
The intensity scores indicated an upregulation of IL-17R expression
in the TSC samples compared with the CTX samples (Table 2).
Double-labeling experiments revealed that IL-17R and GFAP were
co-expressed in astrocytes (Fig. 3E). Moreover, most IL-17R+ GCs
(Fig. 3F) and DNs (Fig. 3G) were NF200+.
4. Discussion
Recent observations indicate that activation of both the innate and
adaptive immune responses has been accepted as a striking feature
that occurs in epilepsy-associated cortical tuber and proinﬂammatory
cytokines may play critical roles in epileptogenesis(Boer et al., 2008;
Vezzani et al., 2008, 2011). In the present study, we found that the
expression of IL-17 and IL-17R is upregulated in cortical tubers of
TSC at protein levels. Intriguingly, IL-17 and IL-17R are expressed at
high levels in misshapen cells (such as DNs, GCs) and glial (such asFig. 3. Cell-speciﬁc distribution of IL-17R in cortical tubers of TSC. (A and B) IL-17R IR in CTX
(arrowheads in A and B), in endothelial cells (inset, B) in gray matter (GM) and white matte
(double arrows in C) and DNs (arrows in D) with different shapes and sizes. Moderate
colocalization of IL-17R (green) with GFAP (red) in glial cells (arrowheads,) but not in G
with NF200 (red) in GCs (F) and in DNs (G). Sections are counterstained with hematoxylinreactive astrocytes and microglia) as well as the endothelial cells of
blood vessels. The cell-speciﬁc distribution pattern of the IL-17 sys-
tem in cortical tuber of TSC suggests that it may be involved in the
epileptogenicity of cortical tuber in TSC.
Previous studies observed that IL-17 is upregulated in several neuro-
logical disorders such as autoimmune diseases, neurodegeneration,
stroke and refractory epilepsy with FCDs (Wang et al., 2009; Xu and
Cao, 2010; Muls et al., 2012; He et al., 2013). In our study, high levels
of IL-17 protein were detected in cortical tuber tissue homogenate.
Moreover, immunohistochemistry analyses showed that the IL-17 IR
was generally located in misshapen cells (such as DNs and GCs) and
glial. Intriguingly, there was coexpression of the neuronal markers
NF200, but not the astrocytic marker GFAP, in IL-17+ DNs and GCs,
suggesting that they have a neuronal lineage in TSC. Meanwhile, we
found that the GFAP+ reactive astrocytes and the HLA+ microglia
expressed high levels of IL-17 in cortical tubers of TSC. In the brain, in-
nate immunity cell types comprise resident neurons, astrocytes, and
microglia, which produce proinﬂammatory cytokines (Granata et al.,
2011). All these suggested that innate immunity cells are the resources
of IL-17 and it may participate in innate immunity response in TSC.
Nevertheless, the mechanisms of IL-17 upregulation in TSC are not
clear. Abundant evidence indicates that cortical tubers are the epilep-
togenic foci in TSC (Wang et al., 2007). Seizure activity and abnormal. Weak to moderate IL-17R IR in neurons (arrows in A) and weak IL-17R IR in glial cells
r (WM). (C and D) IL-17R IR in TSC. Strong IL-17R IR in glial cells (arrowheads in C), GCs
to strong IL-17R IR in endothelial cells (inset, C). (E) The merged images show the
Cs (arrows). (F and G) Confocal images showing the colocalization of IL-17R (green)
(A–D) or DAPI (E–G). The bars indicate (A–D) 50 μm; (E) 30 μm; and (F, G) 20 μm.
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symptom and histological features of epilepsy patients with TSC and
all of the samples were obtained from lesionectomy in this study. It
is therefore possible that misshapen cells, astrocytes, and microglia
in cortical tubers may also express and release IL-17 in response to
seizure activities.
Recent studies indicated that the mTOR pathway not only plays a
role in regulating cell growth and size (Fingar et al., 2002), but also
regulates the induction of inﬂammatory mediators (Potter et al.,
2001; Lim et al., 2003). Yurchenko et al. found that rapamycin strong-
ly inhibits the induction of IL-17 (Yurchenko et al., 2012). Thus,
the activation of mTOR pathway due to the mutation of TSC1 and/or
TSC2 genes may contribute to the up-regulation of IL-17 in TSC.
We found that the IL-17R IRwas generally located inmisshapen cells
(such as DNs and GCs) and glial. Misshapen cells may be the intrinsic
“pacemakers” that initiate and drive the epileptiform activity in TSC
(Cepeda et al., 2003; Wong, 2008). The activation of astrocytes and
microglia is represented within cortical tubers and is involved in the
generation of seizures (Wong, 2008; Najjar et al., 2011). Our previous
study and other groups have provided evidence indicating that IL-6
and IL-1β are overexpressed in cortical tubers of TSC and may contrib-
ute to the high epileptogenicity of the cortical tubers in TSC through
their functional receptors (Ravizza et al., 2006; Shu et al., 2010), both
of which could be induced by IL-17 (Jovanovic et al., 1998; Ma et al.,
2010). Moreover, Richter et al. reported that IL-17 increased the excit-
ability of dorsal root ganglia (DRG) neurons through IL-17R (Richter
et al., 2012). It is likely, therefore, that the persistent upregulation of
IL-17 and IL-17R may be involved in the epileptogenicity of cortical tu-
bers in TSC.
Autocrine or paracrine activation of IL-17R in response to IL-17 re-
leased by neurons and/or glial cells may contribute to the recurrence
or exacerbation of seizure activity in TSC.
In this study, the upregulated expressions of IL-17 and IL-17R
were observed in the endothelial cells of blood vessels in TSC. Kebir
et al. have demonstrated that IL-17 promotes BBB disruption via bind-
ing with IL-17R in human endothelial cells (Kebir et al., 2007). Recent
studies using IL-17 knock-out mice demonstrated the prevention of
experimental autoimmune encephalomyelitis induced BBB disrup-
tion (Huppert et al., 2010). Boer et al. reported BBB disruption in cor-
tical tubers of TSC, as demonstrated by perivascular parenchymal
leakage of serum albumin, with uptake into astrocytes (Boer et al.,
2008). Interestingly, albumin uptake into astrocytes has been shown
to affect K+ homeostasis, facilitating neuronal hyperexcitability and
epileptiform activity (Ivens et al., 2007). Therefore, we speculate
that IL-17 disrupts the BBB through interaction with IL-17R in endo-
thelial cells and, subsequently, exacerbates seizure activity in TSC.
CD4+ and CD8+ T-lymphocytes were detected within TSC and
FCDII cortical lesions (Boer et al., 2008; Iyer et al., 2010). Interestingly,
we found that CD4+ but not CD8+ T-lymphocytes expressed high
levels of IL-17 in the TSC specimens, suggesting that adaptive immu-
nity cells are the resources of IL-17 and it may participate in adaptive
immunity response in TSC. Clinical and experimental data suggest
that adaptive immunity response may be involved in epilepsy.
The factors that trigger these T lymphocyte inﬁltrations in cortical
tubers of TSC are not known. Recent studies indicated that inhibiting
BBB disruption induced by IL-17 leads to lower inﬁltration of T lym-
phocyte in CNS (Huppert et al., 2010). Strong CCL2 (or MCP-1) IR
was detected in cortical tuber specimens, but moderate CCL2 IR was
detected in histologically normal cortex (Boer et al., 2010). Moreover,
IL-17 promotes the transmigration of human ex vivo T lymphocytes
via enhanced secretion of the chemokine CCL2 (Kebir et al., 2007).
Together, these results suggest that IL-17 may be the factor that pro-
motes the transmigration of T-lymphocytes through the enhanced
secretion of CCL2 in TSC patients.
In conclusion, our results demonstrate an association between the
overexpression of IL-17, IL-17R and the epileptogenesis in TSC. Our IHCstudy further displayed that IL-17 system was speciﬁcally distributed in
the innate immunity cells (DNs, GCs, astrocytes, and microglia) and
adaptive immunity cells (T-lymphocytes) as well as the endothelial
cells of blood vessels, suggesting that these cells are the major sources
of IL-17 and itmay participate in innate immunity response and adaptive
immunity response as well as BBB disruption. Accordingly, we speculate
that IL-17 may be involved in the epileptogenicity of cortical tubers in
TSC by accelerating the severity of inﬂammatory response and BBB
disruption, which requires further investigation in animal models of
epilepsy.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.jneuroim.2013.05.007.
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